Yale University: Depressive Disorder trials

The registry lists 22 Depressive Disorder studies with Yale University as lead sponsor. 1 are open to participants now and 8 have results posted.

Phase 1 2Phase 2 5Phase 3 3Phase 4 1No phase 12(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal EffectsRecruitingNCT05786066Phase 2
• Ketamine for Severe Adolescent Depression: Intermediate-term Safety and EfficacyTerminatedNCT03889756Phase 2/3Results posted
• Ketamine Infusion for Adolescent Depression and AnxietyCompletedNCT02579928Phase 4Results posted
• PET Imaging of mGLuR5 With Drug ChallengeCompletedNCT01691092Not applicableResults posted
• Efficacy and Tolerability of Riluzole in Treatment Resistant DepressionCompletedNCT01204918Phase 2Results posted
• Levetiracetam in the Management of Bipolar DepressionCompletedNCT00566150Not applicableResults posted
• Ceftriaxone in the Management of Bipolar DepressionTerminatedNCT00566111Not applicableResults posted
• Mecamylamine for the Treatment of Patients With Depression and Alcohol DependenceCompletedNCT00563797Phase 3Results posted
• Naltrexone & SSRI in Alcoholics With Depression/PTSDCompletedNCT00338962Phase 3Results posted
• Adolescent Depression: Video Ads on InstagramCompletedNCT05755165Not applicable
• Single-Session Intervention Targeting Emotional Awareness, Clarity, and Acceptance to Reduce Depression/AnxietyCompletedNCT05109507Not applicable
• Reducing Depression-related Stigma and Increasing-treatment Seeking Among Black AdolescentsCompletedNCT04890990Not applicable
• Detection of Postoperative Respiratory Depression in High Risk Patients Utilizing Minute Ventilation MonitoringCompletedNCT04017702
• Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response, Pilot TrialCompletedNCT03367533Phase 1
• Cognitive Therapy to Sustain the Antidepressant Effects of Intravenous Ketamine in Treatment-resistant DepressionCompletedNCT03027362Not applicable
• Integrating HIV and Depression Self-Care to Improve Adherence in Perinatal WomenCompletedNCT03016546Not applicable
• Intracranial Atherosclerosis and Depression After Coronary Artery Bypass GraftCompletedNCT01838356
• Trial of Ketamine and Lithium Therapy in Bipolar DepressionWithdrawnNCT01768767Phase 2
• Ketamine for Depression and Alcohol DependenceCompletedNCT01551329Phase 1
• Cortical GABA Concentrations in InsomniaCompletedNCT00765752
• Duloxetine for the Treatment of Postpartum DepressionWithdrawnNCT00617045Not applicable
• Nicotinic Receptor Augmentation of SSRI AntidepressantsCompletedNCT00319319Phase 2